Table 1.
Patient and treatment characteristics
| Parameter | Nr |
|---|---|
| A. Patient and tumor characteristics | |
| Age (years) Median (range) | 67 (36-87) |
| Gender | |
| Male | 24 (56%) |
| Female | 19 (44%) |
| Tumor location a | |
| IHCC | 17 (40%) |
| EHCC | 26 (60%) |
| Treatment | |
| Primary inoperable | 26 (70%) |
| Recurrent | 8 (22%) |
| Positive margins | 3 (08%) |
| Prior therapies | |
| Resection | 12 (32%) |
| Chemotherapy | 6 (16%) |
| Gemcitabine/Oxaliplatin | 1 |
| Gemcitabine | 1 |
| Capecitabin | 1 |
| 5-FU | 1 |
| Therapies after SBRT | |
| Chemotherapy | 13 (35%) |
| TACE | 1 (03%) |
| CA 19-9 (U/ml) Median (IQR) | 149 (20-499) |
| Bilirubin (mg/dl) Median (range) | 0.8 (0.5-21) |
| GTV Diameter (cm)a Median (IQR) | 4.9 (3.4-8.2) |
| PTV Volume (cm3)a Median (IQR) | 124 (60-329) |
| B. Treatment characteristics | |
| Prescribed dose (Gy)a | |
| Median (IQR) | 45 (38-48) |
| Maximum point dose (Gy)a | |
| Median (IQR) | 51 (44-58) |
| Mean PTV dose (Gy)a | |
| Median (IQR) | 47 (42-51) |
| EQD210 (Gy)a | |
| Median (IQR) | 56 (47-61) |
| EQD210 Maximum point dose (Gy) | |
| Median (IQR) | 65 (59-85) |
| EQD210 Mean dose (Gy) | |
| Median (IQR) | 63 (53-82) |
IHCC Intrahepatic cholangiocarcinoma, EHCC Extrahepatic cholangiocarcinoma, 5-FU 5-Fluoruracil, IQR interquartile range, EQD2 equieffective doses in 2 Gy (α/β = 10)
aper lesion